Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH Drug Repurposing Program Produces Surprise Overlaps

Executive Summary

Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.

You may also be interested in...

NIH Translational Science Center Gets Expanded Powers In Cures Bill

When NCATS was created, industry was wary of allowing Phase III trials; now sponsors embrace it.

Clinical Trial Data Release: Be Careful What You Wish For, Industry Exec Says

Some advocates and researchers say that data availability could inform repurposing opportunities for products, but a GSK exec cautions that it could just as easily bring a flood of confusing information.

NCATS May Consider Requesting “Active” Compounds For Repurposing Program

With its first set of grants funded, NCATS wonders whether it should try to solicit repurposing candidates that are still being worked on, rather than only using those that have been shelved.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts